Yahoo Web Search

Search results

  1. The Global Fund invests US$4 billion a year to defeat HIV, TB and malaria and ensure a healthier, safer, equitable future for all. We unite the world to find solutions that have the most impact, and we take them to scale worldwide. It’s working. We won’t stop until the job is finished.

    • Funding
    • Prevention
    • Testing and Treatment
    The Global Fund provides 65% of all international financing for malaria programs.
    We have invested more than US$17.9 billion in malaria control programs as of June 2023.
    Since January 2021, we have increased malaria grants by 23% on average.
    220 million mosquito nets distributed to protect families from malaria in 2022.
    8.5 million structures covered by indoor residual spraying in 2022.
    37.1 million children covered by seasonal malaria chemoprevention in 2022.
    14.6 million pregnant women received preventive therapy for malaria in 2022.
    321 million suspected cases of malaria tested in 2022.
    166 million cases of malaria treated in 2022.
  2. The Challenge. Tuberculosis (TB) is one of the world’s leading infectious disease killers. More than 1.6 million people died of TB in 2021, including people living with HIV. It is the leading killer of people living with HIV, causing 1 in 3 deaths. Colliding crises – climate change, war and deepening inequities within and between countries ...

  3. The Global Fund to Fight AIDS, Tuberculosis and Malaria (or simply the Global Fund) is an international financing and partnership organization that aims to "attract, leverage and invest additional resources to end the epidemics of HIV/AIDS, tuberculosis and malaria to support attainment of the Sustainable Development Goals ...

  4. Sep 12, 2022 · The Global Funds 2022 Results Report released today finds a significant rebound in 2021 for programs working to defeat HIV, tuberculosis (TB) and malaria. In 2020, the COVID-19 pandemic had a devastating impact on the fight against the three diseases, leading to the decline of key programmatic results across the three diseases for ...